These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28213356)

  • 21. Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells.
    Wortham M; Jin G; Sun JL; Bigner DD; He Y; Yan H
    PLoS One; 2012; 7(4):e36211. PubMed ID: 22558385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initiation of Otx2 expression in the developing mouse retina requires a unique enhancer and either Ascl1 or Neurog2 activity.
    Kaufman ML; Goodson NB; Park KU; Schwanke M; Office E; Schneider SR; Abraham J; Hensley A; Jones KL; Brzezinski JA
    Development; 2021 Jun; 148(12):. PubMed ID: 34143204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-206, a Cerebellum Enriched miRNA Is Downregulated in All Medulloblastoma Subgroups and Its Overexpression Is Necessary for Growth Inhibition of Medulloblastoma Cells.
    Panwalkar P; Moiyadi A; Goel A; Shetty P; Goel N; Sridhar E; Shirsat N
    J Mol Neurosci; 2015 Jul; 56(3):673-80. PubMed ID: 25859932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
    Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
    J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid.
    Di C; Liao S; Adamson DC; Parrett TJ; Broderick DK; Shi Q; Lengauer C; Cummins JM; Velculescu VE; Fults DW; McLendon RE; Bigner DD; Yan H
    Cancer Res; 2005 Feb; 65(3):919-24. PubMed ID: 15705891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cis-regulatory analysis of Onecut1 expression in fate-restricted retinal progenitor cells.
    Patoori S; Jean-Charles N; Gopal A; Sulaiman S; Gopal S; Wang B; Souferi B; Emerson MM
    Neural Dev; 2020 Mar; 15(1):5. PubMed ID: 32192535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
    Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
    Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OTX2 Transcription Factor Controls Regional Patterning within the Medial Ganglionic Eminence and Regional Identity of the Septum.
    Hoch RV; Lindtner S; Price JD; Rubenstein JL
    Cell Rep; 2015 Jul; 12(3):482-94. PubMed ID: 26166575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OTX2 is a therapeutic target for retinoblastoma and may function as a common factor between C-MYC, CRX, and phosphorylated RB pathways.
    Li J; Di C; Jing J; Di Q; Nakhla J; Adamson DC
    Int J Oncol; 2015 Nov; 47(5):1703-10. PubMed ID: 26397460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
    Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
    Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-219 inhibits the proliferation, migration and invasion of medulloblastoma cells by targeting CD164.
    Shi JA; Lu DL; Huang X; Tan W
    Int J Mol Med; 2014 Jul; 34(1):237-43. PubMed ID: 24756834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas.
    de Haas T; Oussoren E; Grajkowska W; Perek-Polnik M; Popovic M; Zadravec-Zaletel L; Perera M; Corte G; Wirths O; van Sluis P; Pietsch T; Troost D; Baas F; Versteeg R; Kool M
    J Neuropathol Exp Neurol; 2006 Feb; 65(2):176-86. PubMed ID: 16462208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing.
    Hovestadt V; Jones DT; Picelli S; Wang W; Kool M; Northcott PA; Sultan M; Stachurski K; Ryzhova M; Warnatz HJ; Ralser M; Brun S; Bunt J; Jäger N; Kleinheinz K; Erkek S; Weber UD; Bartholomae CC; von Kalle C; Lawerenz C; Eils J; Koster J; Versteeg R; Milde T; Witt O; Schmidt S; Wolf S; Pietsch T; Rutkowski S; Scheurlen W; Taylor MD; Brors B; Felsberg J; Reifenberger G; Borkhardt A; Lehrach H; Wechsler-Reya RJ; Eils R; Yaspo ML; Landgraf P; Korshunov A; Zapatka M; Radlwimmer B; Pfister SM; Lichter P
    Nature; 2014 Jun; 510(7506):537-41. PubMed ID: 24847876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIF1A is Overexpressed in Medulloblastoma and its Inhibition Reduces Proliferation and Increases EPAS1 and ATG16L1 Methylation.
    Cruzeiro GAV; Dos Reis MB; Silveira VS; Lira RCP; Carlotti CG; Neder L; Oliveira RS; Yunes JA; Brandalise SR; Aguiar S; Eterovic AK; Tone LG; Scrideli CA; Valera ET
    Curr Cancer Drug Targets; 2018; 18(3):287-294. PubMed ID: 28302031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic amplification of orthodenticle homologue 2 in medulloblastomas.
    Boon K; Eberhart CG; Riggins GJ
    Cancer Res; 2005 Feb; 65(3):703-7. PubMed ID: 15705863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid hormone suppresses medulloblastoma progression through promoting terminal differentiation of tumor cells.
    Yang Y; Valdés-Rives SA; Liu Q; Gao T; Burudpakdee C; Li Y; Tan J; Tan Y; Koch CA; Rong Y; Houser SR; Wei S; Cai KQ; Wu J; Cheng SY; Wechsler-Reya R; Yang ZJ
    Cancer Cell; 2024 Aug; 42(8):1434-1449.e5. PubMed ID: 39137728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.
    Ferrucci V; de Antonellis P; Pennino FP; Asadzadeh F; Virgilio A; Montanaro D; Galeone A; Boffa I; Pisano I; Scognamiglio I; Navas L; Diana D; Pedone E; Gargiulo S; Gramanzini M; Brunetti A; Danielson L; Carotenuto M; Liguori L; Verrico A; Quaglietta L; Errico ME; Del Monaco V; D'Argenio V; Tirone F; Mastronuzzi A; Donofrio V; Giangaspero F; Picard D; Remke M; Garzia L; Daniels C; Delattre O; Swartling FJ; Weiss WA; Salvatore F; Fattorusso R; Chesler L; Taylor MD; Cinalli G; Zollo M
    Brain; 2018 May; 141(5):1300-1319. PubMed ID: 29490009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas: "it's a numbers game"-implications for WNT medulloblastoma dose-reduction clinical trials.
    Gottardo NG
    Acta Neuropathol; 2023 Jan; 145(1):145-147. PubMed ID: 36403175
    [No Abstract]   [Full Text] [Related]  

  • 39. Single-Cell Chromatin Accessibility Analysis Reveals Subgroup-Specific TF-NTR Regulatory Circuits in Medulloblastoma.
    Gao X; Zhuang Q; Li Y; Li G; Huang Z; Chen S; Sun S; Yang H; Jiang L; Mao Y
    Adv Sci (Weinh); 2024 Aug; 11(30):e2309554. PubMed ID: 38884167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hmga2 is necessary for Otx2-dependent exit of embryonic stem cells from the pluripotent ground state.
    Navarra A; Musto A; Gargiulo A; Petrosino G; Pierantoni GM; Fusco A; Russo T; Parisi S
    BMC Biol; 2016 Mar; 14():24. PubMed ID: 27036552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.